A kétoldali subthalamicus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében

Translated title of the contribution: Analysis of antiparkinsonian drug reduction after bilateral subthalamic deep brain stimulation

Georgina Fehér, István Balás, S. Komoly, T. Dóczi, J. Janszky, Zsuzsanna Aschermann, Éva Balázs, Ferenc Nagy, N. Kovács

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background - Bilateral deep brain stimulation of the subthalamic nuclei (STN) is a well-established and cost-effective treatment in advanced PD. Objectives - To quantitatively analyze the change in use of antiparkinsonian drugs one year after subthalamic deep brain stimulator (DBS) implantation in patients with idiopathic Parkinson's disease (PD). Patients and methods - Eighteen consecutive patients with advanced PD underwent bilateral STN DBS implantation were involved in the study. The stimulation achieved a stable and clear clinical benefit in all of the cases. One year after the implantation, drug usage of patients was analyzed and correlated with the postoperative symptomatic improvement measured by the modified Hoehn-Yahr, Schwab and England, and Unified Parkinson's Disease Rating Scales. Because none of the investigated variables followed the normal distribution, non-parametric Wilcoxon signed-rank, McNemar and Kendell's τ tests were applied. Results - Preoperatively, the patients used 12.05±4.57 tablets a day out of 3.19±0.97 different antiparkinsonian drugs, which was significantly reduced by deep brain stimulation to the application of 7.00±2.96 tablets out of 1-3 (1.84±0.76) drugs (p

Original languageHungarian
Pages (from-to)314-319
Number of pages6
JournalIdeggyógyászati szemle
Volume63
Issue number9-10
Publication statusPublished - Sep 30 2010

Fingerprint

Antiparkinson Agents
Deep Brain Stimulation
Parkinson Disease
Subthalamic Nucleus
Pharmaceutical Preparations
Tablets
Normal Distribution
Brain
England
Health Care Costs

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

A kétoldali subthalamicus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében. / Fehér, Georgina; Balás, István; Komoly, S.; Dóczi, T.; Janszky, J.; Aschermann, Zsuzsanna; Balázs, Éva; Nagy, Ferenc; Kovács, N.

In: Ideggyógyászati szemle, Vol. 63, No. 9-10, 30.09.2010, p. 314-319.

Research output: Contribution to journalArticle

Fehér, Georgina ; Balás, István ; Komoly, S. ; Dóczi, T. ; Janszky, J. ; Aschermann, Zsuzsanna ; Balázs, Éva ; Nagy, Ferenc ; Kovács, N. / A kétoldali subthalamicus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében. In: Ideggyógyászati szemle. 2010 ; Vol. 63, No. 9-10. pp. 314-319.
@article{cdbd50fc44804ebcbdafb351a7f00536,
title = "A k{\'e}toldali subthalamicus stimul{\'a}ci{\'o} hat{\'e}konys{\'a}ga az antiparkinson gy{\'o}gyszerel{\'e}s v{\'a}ltoztat{\'a}s{\'a}nak t{\"u}kr{\'e}ben",
abstract = "Background - Bilateral deep brain stimulation of the subthalamic nuclei (STN) is a well-established and cost-effective treatment in advanced PD. Objectives - To quantitatively analyze the change in use of antiparkinsonian drugs one year after subthalamic deep brain stimulator (DBS) implantation in patients with idiopathic Parkinson's disease (PD). Patients and methods - Eighteen consecutive patients with advanced PD underwent bilateral STN DBS implantation were involved in the study. The stimulation achieved a stable and clear clinical benefit in all of the cases. One year after the implantation, drug usage of patients was analyzed and correlated with the postoperative symptomatic improvement measured by the modified Hoehn-Yahr, Schwab and England, and Unified Parkinson's Disease Rating Scales. Because none of the investigated variables followed the normal distribution, non-parametric Wilcoxon signed-rank, McNemar and Kendell's τ tests were applied. Results - Preoperatively, the patients used 12.05±4.57 tablets a day out of 3.19±0.97 different antiparkinsonian drugs, which was significantly reduced by deep brain stimulation to the application of 7.00±2.96 tablets out of 1-3 (1.84±0.76) drugs (p",
keywords = "Deep brain stimulation, Levodopa, Parkinson's disease, Subthalamic nucleus",
author = "Georgina Feh{\'e}r and Istv{\'a}n Bal{\'a}s and S. Komoly and T. D{\'o}czi and J. Janszky and Zsuzsanna Aschermann and {\'E}va Bal{\'a}zs and Ferenc Nagy and N. Kov{\'a}cs",
year = "2010",
month = "9",
day = "30",
language = "Hungarian",
volume = "63",
pages = "314--319",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "9-10",

}

TY - JOUR

T1 - A kétoldali subthalamicus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében

AU - Fehér, Georgina

AU - Balás, István

AU - Komoly, S.

AU - Dóczi, T.

AU - Janszky, J.

AU - Aschermann, Zsuzsanna

AU - Balázs, Éva

AU - Nagy, Ferenc

AU - Kovács, N.

PY - 2010/9/30

Y1 - 2010/9/30

N2 - Background - Bilateral deep brain stimulation of the subthalamic nuclei (STN) is a well-established and cost-effective treatment in advanced PD. Objectives - To quantitatively analyze the change in use of antiparkinsonian drugs one year after subthalamic deep brain stimulator (DBS) implantation in patients with idiopathic Parkinson's disease (PD). Patients and methods - Eighteen consecutive patients with advanced PD underwent bilateral STN DBS implantation were involved in the study. The stimulation achieved a stable and clear clinical benefit in all of the cases. One year after the implantation, drug usage of patients was analyzed and correlated with the postoperative symptomatic improvement measured by the modified Hoehn-Yahr, Schwab and England, and Unified Parkinson's Disease Rating Scales. Because none of the investigated variables followed the normal distribution, non-parametric Wilcoxon signed-rank, McNemar and Kendell's τ tests were applied. Results - Preoperatively, the patients used 12.05±4.57 tablets a day out of 3.19±0.97 different antiparkinsonian drugs, which was significantly reduced by deep brain stimulation to the application of 7.00±2.96 tablets out of 1-3 (1.84±0.76) drugs (p

AB - Background - Bilateral deep brain stimulation of the subthalamic nuclei (STN) is a well-established and cost-effective treatment in advanced PD. Objectives - To quantitatively analyze the change in use of antiparkinsonian drugs one year after subthalamic deep brain stimulator (DBS) implantation in patients with idiopathic Parkinson's disease (PD). Patients and methods - Eighteen consecutive patients with advanced PD underwent bilateral STN DBS implantation were involved in the study. The stimulation achieved a stable and clear clinical benefit in all of the cases. One year after the implantation, drug usage of patients was analyzed and correlated with the postoperative symptomatic improvement measured by the modified Hoehn-Yahr, Schwab and England, and Unified Parkinson's Disease Rating Scales. Because none of the investigated variables followed the normal distribution, non-parametric Wilcoxon signed-rank, McNemar and Kendell's τ tests were applied. Results - Preoperatively, the patients used 12.05±4.57 tablets a day out of 3.19±0.97 different antiparkinsonian drugs, which was significantly reduced by deep brain stimulation to the application of 7.00±2.96 tablets out of 1-3 (1.84±0.76) drugs (p

KW - Deep brain stimulation

KW - Levodopa

KW - Parkinson's disease

KW - Subthalamic nucleus

UR - http://www.scopus.com/inward/record.url?scp=78349236301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349236301&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 314

EP - 319

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 9-10

ER -